Table 3.
The clinical application of Corydalis saxicola Bunting.
| Class | Drugs | Cases | Result | Adverse Reaction | References |
|---|---|---|---|---|---|
| Icteric hepatitis | CSBI | unknow | The total effective rate of the treatment group was 87.5%, the control group was 62.5% (p < 0.01) | [85] | |
| CSBI | 42 | Significantly decreased contents of ALT, AST, γ-GT and TBIL (p < 0.05). | [86] | ||
| CSBI | 60 | The clinical symptoms and liver function in the treatment group were better than those in the control group (p < 0.05) | [87] | ||
| CSBI | 82 | Significantly improved symptoms of fatigue, abdominal distension, hepatalgia and poor appetite; obvious decrease of transaminase and bilirubin | [82] | ||
| CSBI | 98 | Improvement rate of poor appetite, hepatalgia, fatigue and abdominal distension was 85.7%, 84.4%, 76.8% and 87.8%, respectively, summary improvement is 83.4%. Significantly decreased contents of ALT, TBIL | [88] | ||
| CSBI | 29 | The total effective rate of the treatment group was 93.1%, the control group was 71.0% (p < 0.05) | [89] | ||
| CSBI | 1 | Caused allergic reactions | Itching, palpitating, chills, fever | [83] | |
| Salvia miltiorrhiza Bge & Yinzhihuang & CSB | 90 | The total effective rate of the treatment group was 96.0%, the control group was 82.5% (p < 0.05) | [90] | ||
| Salvia miltiorrhiza Bge & Yinzhihuang & CSB | 90 | The total effective rate of the treatment group was 96.0%, the control group was 82.5% (p < 0.05) | Precardiac discomfort, urticaria, skin itching, pain at the injection site | [91] | |
| Viral hepatitis | CSBI | 93 | The total effective rate of the treatment group was 91.7%, the control group was 68.9% (p < 0.03) | There were no adverse reactions | [92] |
| CSBI | 50 | Significantly decreased ALT and TBIL (p < 0.05), the total effective rate of the treatment group was 94.0% | [93] | ||
| CSBI | 208 | TBil of treatment group dropped by 71.22%, the control group was 44.30% (p < 0.01); Dbil of treatment group dropped by 67.53% (p < 0.01) | low-grade fever | [94] | |
| CSBI | 360 | Significant difference in improvement rate of hepatalgia and poor appetite (p < 0.01), decreased the levels of T-BILI, D-BILI and ALT | [95] | ||
| CSBI | 60 | The total effective rate of the treatment group was 88.23%, the control group was 76.92% (p < 0.05) | Local vascular pain | [96] | |
| CSBI | 33 | Decreased the contents of ALT and AST in a short time, improved protein metabolism | [97] | ||
| Compound Danshen & CSB | 100 | The total effective rate of the treatment group was 96.14%, the control group was 64.58% (p < 0.01) | Mild rash | [98] | |
| Acute and chronic hepatitis | CSBI | 93 | The total effective rate of the treatment group was 91.7%, the control group was 68.9% (p < 0.03) | There were no adverse reactions | [92] |
| Magnesium isoglycyrrhizinate & CSB | 65 | The total effective rate of the treatment group was 89.23%, the control group was 70.14% (p < 0.05) | [99] | ||
| CSB & Telbivudine | 80 | The total effective rate of the treatment group was 72.5%, the control group was 50% (p < 0.05) | [100] | ||
| CSB & Danshen injection | 70 | Significantly decreased ALT and TBIL, increased the ratio of A/G | [101] | ||
| Liver cancer | CSBI | 96 | The total effective rate of the treatment group was 83.3%, the control group was 72.9% (p < 0.05), Significantly decreased ALT and AST | [102] | |
| CSBI | 96 | The total effective rate of the treatment group was 83.3%, the control group was 72.9% (p < 0.05), the QOL of the treatment group (68.6±7.2) more than the control group (60.5±6.1) after treatment (p < 0.05) | [103] | ||
| CSBI | 96 | The total effective rate of the treatment group was 79.2%, the control group was 50.0% (p < 0.05), effectively improve the levels of serum IL-2, IFN-γ and TNF-α, better than the control group | [104] | ||
| CSBI | 96 | The total effective rate of the treatment group was 81.3%, the control group was 70.8% (p < 0.05), after treatment, the INF-γ, IL-4 and the ratio of INF-γ/IL-4 in the observation group were significantly better than those in the control group (p < 0.05) | [105] | ||
| CSBI | 120 | After treatment, the liver function recovery effect of the injection group was better than that of the control group (p < 0.05) | fever, skin itch; the injection group (6.7%), the control group (8.3%) |
[106] | |
| CSBI | 96 | The total effective rate of the treatment group was 72.9%, the control group was 52.1% (p < 0.05) | [107] | ||
| CSBI | 96 | The total effective rate of the treatment group was 83.3%, the control group was 64.4% (p < 0.05) | The adverse effects rate of the treatment group was 20.8%, the control group was 39.6% (p < 0.05) | [108] | |
| CSBI | 96 | The total effective rate of the treatment group was 97.92%, the control group was 87.50% (p < 0.05) | The adverse effects rate of the treatment group was 10.42%, the control group was 39.6% (p < 0.05) | [109] | |
| CSBI | 110 | Quality of life improvement rate in the treatment group was 81.82%, the control group was 52.73% (p < 0.05) | [110] | ||
| CSBI | 42 | Significantly decreased the levels of ALT, AST, TBIL and γ-GT | Fever, shiver, skin itch | [86] | |
| CSBI | 60 | Significantly decreased the level of AFP, the white blood cell count goes up | [111] | ||
| CSBI | 46 | Significantly increased the level of ALT and AST (p < 0.05), decreased TBIL (p > 0.05) | [112] | ||
| CSBI & Octreotide | 116 | The total effective rate of the treatment group was 96.4%, the control group was 92.9% (p < 0.05) | The adverse effects rate of the treatment group was 5.2%, the control group was 17.2% (p < 0.05) | [113] | |
| Hyperbilirubinemia | CSBI | 126 | The total effective rate of the treatment group was 95.3%, the control group was 93.6% (p > 0.05) | Diarrhea, rash | [114] |
| Others | |||||
| Rectal cancer | CSBI | 68 | The total effective rate of the treatment group was 38.24%, the control group was 5.88% (p < 0.05) | [115] | |
| Hemorrhagic fever with renal syndrome | CSBI & Ribavirin | 60 | Significantly decreased the duration of fever period and oliguria period, obvious the recovery of AST, ALT, LDH and BUN than the control group (p < 0.05) | [116] | |
| Liver cirrhosis | CSBI | 60 | Significantly effect in relieving symptoms, protecting liver and gallbladder | [117] |